Novo Nordisk and the associated logos are trademarks of Novo Nordisk A/S.

Novo Nordisk is a global leader in chronic disease management with a century-long heritage in metabolic and endocrine care. With deep expertise in diabetes and obesity, the company is leveraging its scientific leadership to address metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)—two emerging public health challenges closely linked to cardiometabolic risk and insulin resistance.

Novo Nordisk’s therapeutic strategy is centered on hormone-based approaches that target the underlying metabolic dysfunction driving MASLD/MASH progression. Its most advanced asset in this space is semaglutide, a GLP-1 receptor agonist with clinically proven benefits in reducing liver fat content, improving insulin sensitivity, and lowering systemic inflammation. Semaglutide is currently being studied in Phase 2 and Phase 3 clinical trials for MASH resolution and fibrosis improvement, with or without combination agents.

Recognizing that monotherapy may be insufficient for reversing advanced disease, Novo Nordisk is also investing in multi-mechanism combination regimens—pairing semaglutide with FXR agonists, tri-agonists, or anti-fibrotic agents—to maximize therapeutic benefit across the MASH disease spectrum. This integrated approach is informed by the company’s comprehensive understanding of the gut-liver axis and cardiometabolic health.

With a focus on prevention, disease modification, and long-term cardiometabolic risk reduction, Novo Nordisk is uniquely positioned to lead the transformation of MASH care. Its holistic portfolio, encompassing both monotherapy and rational combination strategies, underscores a bold commitment to improving liver and metabolic outcomes for millions of patients worldwide.